Post-Transplant Malignancies following Pancreas Transplantation: Incidence and Implications on Long-Term Outcome from a Single-Center Perspective

• Published in: Journal of clinical medicine Vol. 10; no. 21; p. 4810
• Main Authors: Krendl, Felix J., Messner, Franka, Bösmüller, Claudia, Scheidl, Stefan, Cardini, Benno, Resch, Thomas, Weissenbacher, Annemarie, Oberhuber, Rupert, Maglione, Manuel, Schneeberger, Stefan, Öfner, Dietmar, Margreiter, Christian
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 20.10.2021; MDPI
• Subjects: Bladder; Cancer; Chemotherapy; Clinical medicine; Disease prevention; Induction therapy; Leukopenia; Melanoma; Pancreas transplants; Patients; Skin cancer; Statistical analysis; Steroids; Veins & arteries
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10214810

Chronic immunosuppression is associated with an increased risk of malignancy. The main objective of this study is to evaluate the incidence and effect of post-transplant malignancies (PTMs) following pancreas transplantation. The 348 first pancreas transplants performed between 1985 and 2015 were retrospectively analyzed in this study. Incidences of PTMs, as well as patient and graft survival, were evaluated. Out of 348 patients, 71 (20.4%) developed a PTM. Median time to diagnosis was 130 months. Thirty-six patients (50.7%) developed skin cancers (four patients with melanoma, 32 with NMSCs). Solid organ malignancy occurred in 25 (35.2%), hematologic malignancy in ten patients (14.1%). Affected patients were transplanted earlier [2000 (IQR 1993−2004) vs. 2003 (IQR 1999−2008); p < 0.001]. No differences in induction therapy were seen, both groups demonstrated comparable patient and graft survival. Pancreas transplant recipients with solid organ and hematologic malignancies had a three- and six-fold increased hazard of death compared to those with skin cancers [aHR 3.04 (IQR 1.17–7.91); p = 0.023; aHR 6.07 (IQR 1.87–19.71); p = 0.003]. PTMs affect every fifth patient following pancreas transplantation. Skin cancers are the most common malignancies accounting for 50% of all PTMs. These results underscore the importance of close dermatologic follow-up.